☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
chronic myeloid leukemia
Novartis' Scemblix (asciminib) Receives the US FDA's Approval for the Treatment of Chronic Myeloid Leukemia
October 29, 2021
Novartis' Asciminib (ABL001) Demonstrate Superiority Over Pfizer's Bosulif in Chronic Myeloid Leukemia Trial
December 9, 2020
Novartis Reports Results of Asciminib (ABL001) in P-III ASCEMBL Study for Chronic Myeloid Leukemia
August 26, 2020
Takeda to Present Results of Iclusig (ponatinib) in P-II OPTIC Study for Chronic Myeloid Leukemia in the Chronic Phase at ASCO and...
June 1, 2020
Xspray Pharma Reports Positive P-I Trial Results of HyNap-Dasa for the Treatment of Chronic Myeloid Leukemia (CML)
September 10, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.